Mark S. Carey - Concepedia

Author

Mark S. Carey

Also Known As

Carey, M. S., M. CAREY, M. Carey, M. S. Carey, M.S. CAREY, M.S. Carey, MARK S. CAREY, Mark Carey, Mark S Carey, Mark S. Carey

Publications

Citations

H-Index

Concepts

All Affiliations

University of British Columbia Western University Princess Margaret Cancer Centre London Health Sciences Centre BC Cancer Agency

About

Mark S. Carey is an author at University of British Columbia specializing in medicine, obstetrics, and gynecology oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.1K
2	Public Health	5	5	111
3	Health Sciences	3	3	224
4	Emergency Medicine	1	1	216
5	Gastroenterology	1	1	216

Mark S. Carey

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
A Phase 3 Trial of Bevacizumab in Ovarian Cancer Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, New England Journal of Medicine	2011	2.1K
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Amit M. Oza, Adrian Cook, Jacobus Pfisterer, The Lancet Oncology	2015	845
Predictors of Large Esophageal Varices in Patients With Cirrhosis Naga Chalasani, Thomas F. Imperiale, Ayaaz Ismail, The American Journal of Gastroenterology VaricesLarge Esophageal VaricesEsophagusHepatologyMedicine	1999	216
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group Amit M. Oza, Elizabeth A. Eisenhauer, G. Stanimir, International Journal of Gynecological Cancer	2004	157
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial Dan Stark, Matthew Nankivell, Éric Pujade-Lauraine, The Lancet Oncology International CollaborationMedicineStandard ChemotherapyCancer ManagementMetronomic Therapy	2013	137
The role of the fallopian tube in ovarian cancer. Alicia A Tone, Shannon Salvador, Sarah J Finlayson, PubMed Gynecologic SurgerySurgical OncologyTumoral PathologyGynecological SurgeryEndocrine-related Cancer	2012	95
The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer Mark S. Carey, Monica Bacon, Dongsheng Tu, Gynecologic Oncology Prognostic BiomarkersProgression-free SurvivalAdvanced Ovarian CancerLongevityMedicine	2007	89
A Phase II Study of Leuprolide in Advanced/Recurrent Endometrial Cancer Al Covens, Gigi Thomas, Peter J. Shaw, Gynecologic Oncology MedicineGynecologyAdvanced/recurrent Endometrial CancerCancer TreatmentOncology	1997	83
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium Stephen Welch, Hal W. Hirte, Mark S. Carey, Gynecologic Oncology MedicineCancer ManagementGynecologyPathologyCancer Treatment	2007	75
Are Uterine Risk Factors More Important Than Nodal Status in Predicting Survival in Endometrial Cancer? Janice S. Kwon, Feng Qiu, Refik Saskin, Obstetrics and Gynecology	2009	74

Page 1